Program
AND017
A development code. Also written as “AND017 capsules”, “AND017 capsules TIW” and “AND017 capsules QW”.
Its studies are mostly in Anemia · Thalassemia · Myelodysplastic Syndromes, led by Kind Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kind Pharmaceuticals | 106 open or running | phase 3since Mar 17, 2026 | Jan 13, 2021 | Dec 2026phase 2 · NCT06302491 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 13, 2021First studies: 2 phase 1 studies in Healthy VolunteersFirst studyNCT04712500, NCT04751539
- Apr 21, 2021Phase 2 study in Renal AnemiaNCT05035641 · 113 enrolled · United States, China
- Feb 22, 2022Phase 2 study in Renal AnemiaNCT05265325 · 175 enrolled · United States, China
- Mar 22, 20234 phase 2 studiesNCT06304103, NCT06302491, NCT06075043 and 1 more
- Mar 17, 20262 phase 3 studies in AnemiaPhase 3 reachedNCT07487727, NCT07494409
Ahead
- Dec 2026Primary completion: phase 2 study in Myelodysplastic SyndromesNCT06304103
- Dec 2026Primary completion: phase 2 study in β -ThalassemiaNCT06302491
- Dec 1, 2026Primary completion: phase 3 study in AnemiaNCT07487727
- Dec 2027Primary completion: phase 2 study in Chemotherapy Induced AnemiaNCT06075030
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07494409Anemia · China | 3 | Recruiting | Oct 30, 2026 | 300 |
| NCT07487727Anemia · China | 3 | Recruiting | Dec 1, 2026 | 240 |
| NCT06304103Myelodysplastic Syndromes · China | 2 | Recruiting | Dec 2026 | 63 |
| NCT06302491β -Thalassemia · China | 2 | Recruiting | Dec 2026 | 64 |
| NCT06075043Cancer-Related Anemia | 2 | Not yet recruiting | May 2028 | 36 |
| NCT06075030Chemotherapy Induced Anemia | 2 | Not yet recruiting | Dec 2027 | 36 |
| NCT05265325Renal Anemia · United States, China | 2 | Completed | Feb 29, 2024 | 175 |
| NCT05035641Renal Anemia · United States, China | 2 | Completed | Jul 5, 2023 | 113 |
| NCT04751539Healthy Volunteers · Australia | 1 | Completed | Feb 11, 2019 | 78 |
| NCT04712500Healthy Volunteers · China | 1 | Completed | Aug 16, 2020 | 14 |
How it is read
Names in the registry
- “AND017”, 6 entries
- “AND017 capsules”, 2 entries
- “AND017 capsules TIW”, 1 entry
- “AND017 capsules QW”, 1 entry
- “AND017 single dose”, 1 entry
Codes read as this program: AND017.
Conditions, from the studies’ own filings
- Anemia, 6 studies
- Thalassemia, 1 study
- Myelodysplastic Syndromes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.